DBV Technologies SA reported additional data from its Phase 3 VITESSE trial evaluating the VIASKIN Peanut Patch in peanut-allergic children aged 4 to 7 years. The company said the trial met its primary endpoint, with 46.6% of children in the VIASKIN Peanut arm meeting responder criteria at 12 months versus 14.8% in the placebo arm (p<0.001). DBV also reported that 82.8% of treated subjects increased their eliciting dose by at least one dose at month 12 versus about 48% on placebo, and 60.1% increased by at least two doses versus 23.4% on placebo. The results were presented as an oral presentation at the AAAAI 2026 Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602281425PRIMZONEFULLFEED1001167406) on February 28, 2026, and is solely responsible for the information contained therein.